RxDoctor Payments Data

Isaac Loose, MD

Retina Specialist · Austin, TXNPI 1821075664

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.1% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $830 and has fallen 82.4% since, to $146 in 2025.

$3,842in general payments, 2019–2025

Across 92 payments — averaging $41.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$460
  • Johnson & Johnson Surgical Vision, Inc.$381
  • Genentech USA, Inc.$358
  • Novartis$346
  • Astellas Pharma US Inc$272
  • Regeneron Healthcare Solutions, Inc.$233
  • plus $2K from 16 others
$163,248in research payments, 2019–2025

Across 37 payments — averaging $4412.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$98K
  • Hoffmann-la Roche Limited$48K
  • AbbVie$18K

What the payments were for

  • Food & beverage$3,54092%
  • Education$932%
  • Entertainment$1444%
  • Other$642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,842 in reported general payments places this provider in the 60th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas

Medicare billing

Part B allowed, 2024
$575,148
Medicare patients
323
Services billed
3,571

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate69$3,804
Ketorolac Tromethamine14$340
MoxifloxacinMoxifloxacin Hcl23$330
Ofloxacin15$169

Paid to pharmacies, not to this prescriber.

Other retina specialist in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →